Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and "triple-negative" breast cancers

Human Pathology

Volumn 41, Issue 3, 2010, Pages 401-406

  Wang, Xiao ^a   Chao, Lan ^b   Li, Xin ^a   Ma, Guohui ^a   Chen, Liansheng ^a   Zang, Yixiu ^a   Zhou, Gengyin ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

"Triple negative" phenotype; Basal like phenotype; Breast cancer; p JNK

Indexed keywords

ANTHRACYCLINE; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHOPROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURGERY; CARCINOGENESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ADENOCARCINOMA, MUCINOUS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CHI-SQUARE DISTRIBUTION; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KERATINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; P-GLYCOPROTEIN; PATIENT SELECTION; PHOSPHORYLATION; UP-REGULATION; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 75949109843     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.08.018     Document Type: Article

References (30)

1. Wu G.S. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 26 (2007) 579-585
2. Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27 (2008) 253-261
3. Liu Y., Shepherd E.G., and Nelin L.D. MAPK phosphatases-regulating the immune response. Nat Rev Immunol 7 (2007) 202-212
4. Dhillon A.S., Hagan S., Rath O., and Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26 (2007) 3279-3290
5. Harkin D.P., Bean J.M., Miklos D., et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97 (1999) 575-586
6. Thangaraju M., Kaufmann S.H., and Couch F.J. BRCA1 facilitates stress induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 275 (2000) 33487-33496
7. Gee J.M., Barroso A.F., Ellis I.O., Robertson J.F., and Nicholson R.I. Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 89 (2000) 177-186
8. Yeh Y.T., Hou M.F., Chung Y.F., et al. Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival. Int J Cancer 118 (2006) 2678-2684
9. Griffin J. The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 28 Suppl 17 (2001) 3-8
10. Miyamoto-Yamasaki Y., Yamasaki M., Tachibana H., and Yamada K. Induction of endoreduplication by a JNK inhibitor SP600125 in human lung carcinoma A 549 cells. Cell Biol Int 31 (2007) 1501-1506
11. Perou C.M., Solie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
12. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
13. Livasy C.A., Karaca G., Nanda R., et al. Phenotype evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
14. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
15. Parikh R.R., Yang Q., Higgins S.A., et al. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiation Oncology Biol Phys 70 (2008) 35-42
16. Small G.W., Shi Y.Y., Higgins L.S., and Orlowski R.Z. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67 (2007) 4459-4466
17. Small G.W., Shi Y.Y., Edmund N.A., Somasundaram S., Moore D.T., and Orlowski R.Z. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66 (2004) 1478-1490
18. Mizuno R., Oya M., Shiomi T., Marumo K., Okada Y., and Murai M. Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells. J Urol 172 (2004) 723-727
19. Codony-Servat J., Tapia M.A., Bosch M., et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5 (2006) 665-675
20. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 (2002) 3628-3636
21. Dalton L.W., Pinder S.E., Elston C.E., et al. Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol 13 (2000) 730-735
22. Ching Y.P., Leong V.Y., Lee M.F., et al. P21-Activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res 67 (2007) 3601-3608
23. O'Hagan R.C., and Hassell J.A. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 16 (1998) 301-310
24. Lee R.J., Albanese C., Fu M., et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20 (2000) 672-683
25. Wulf G.M., Ryo A., Wulf G.G., et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20 (2001) 3459-3472
26. Pakunlu R.I., Cook T.J., and Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res 20 (2003) 351-359
27. Rudas M., Filipits M., Taucher S., et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 81 (2003) 149-157
28. Levresse V., Marek L., Blumberg D., et al. Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. Mol Pharmacol 62 (2002) 689-697
29. Zhou J., Liu M., Aneja R., et al. Reversal of p-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 66 (2006) 445-452
30. Heasley L.E., and Han S.Y. JNK regulation of oncogenesis. Mol Cells 21 (2006) 167-173